{"id":"ferriprox-deferiprone","safety":{"commonSideEffects":[{"rate":null,"effect":"Agranulocytosis"},{"rate":null,"effect":"Neutropenia"},{"rate":"5–10","effect":"Arthralgia"},{"rate":"5–10","effect":"Gastrointestinal disturbance (nausea, abdominal pain)"},{"rate":null,"effect":"Zinc deficiency"}]},"_chembl":{"chemblId":"CHEMBL70927","moleculeType":"Small molecule","molecularWeight":"139.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Deferiprone is a bidentate chelating agent that forms stable complexes with ferric iron (Fe³⁺), preventing iron-catalyzed free radical formation and tissue damage. It crosses cell membranes to access intracellular iron stores, particularly in cardiac myocytes and hepatocytes, and the iron-deferiprone complex is readily excreted in the urine, reducing total body iron burden in iron-overload conditions.","oneSentence":"Deferiprone is an iron chelator that binds excess iron in the body and facilitates its excretion through urine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:24.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Transfusional iron overload in patients with chronic anemia"},{"name":"Iron overload in thalassemia major"}]},"trialDetails":[{"nctId":"NCT02164253","phase":"PHASE2","title":"Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2013-09","conditions":"ALS (Amyotrophic Lateral Sclerosis), Iron Overload","enrollment":23},{"nctId":"NCT07023666","phase":"PHASE2","title":"Early Screening and Treatment of Heart Complication in Sickle Cell Disease","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2025-10-07","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT03591575","phase":"PHASE4","title":"Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children","status":"COMPLETED","sponsor":"Chiesi Canada Corp","startDate":"2018-11-09","conditions":"Beta Thalassemia Major Anemia, Iron Overload","enrollment":64},{"nctId":"NCT02443545","phase":"PHASE4","title":"Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias","status":"TERMINATED","sponsor":"ApoPharma","startDate":"2015-05-21","conditions":"Iron Overload, Sickle Cell Disease, Other Anemias","enrollment":134},{"nctId":"NCT00907283","phase":"PHASE2","title":"Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)","status":"UNKNOWN","sponsor":"Ente Ospedaliero Ospedali Galliera","startDate":"2008-11","conditions":"Neurodegenerative Disease, Iron Overload","enrollment":20},{"nctId":"NCT02635841","phase":"","title":"Compassionate Use of Deferiprone in Patients With PKAN","status":"NO_LONGER_AVAILABLE","sponsor":"Chiesi Canada Corp","startDate":"","conditions":"Pantothenate Kinase-Associated Neurodegeneration","enrollment":""},{"nctId":"NCT02041299","phase":"PHASE4","title":"Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias","status":"TERMINATED","sponsor":"ApoPharma","startDate":"2014-04-17","conditions":"Iron Overload, Sickle Cell Disease, Other Anemias","enrollment":230},{"nctId":"NCT03802916","phase":"PHASE2","title":"Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2019-03-06","conditions":"Iron Overload Due to Repeated Red Blood Cell Transfusions","enrollment":30},{"nctId":"NCT02174848","phase":"PHASE3","title":"Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2014-06","conditions":"Pantothenate Kinase-Associated Neurodegeneration","enrollment":68},{"nctId":"NCT01539837","phase":"PHASE2","title":"A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2012-02","conditions":"Parkinson's Disease","enrollment":22},{"nctId":"NCT02880033","phase":"NA","title":"Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2011-02","conditions":"Parkinson's Disease, Amyotrophic Lateral Sclerosis, Oxidative Stress","enrollment":90},{"nctId":"NCT01284127","phase":"","title":"Observational Study of Deferiprone (Ferriprox®) in the Treatment of Superficial Siderosis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-03","conditions":"Superficial Siderosis","enrollment":38},{"nctId":"NCT01741532","phase":"PHASE3","title":"Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2012-12-13","conditions":"Pantothenate Kinase-Associated Neurodegeneration","enrollment":89},{"nctId":"NCT01709032","phase":"PHASE1, PHASE2","title":"Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2012-09","conditions":"Thalassemia Major With Severe Transfusional Iron Overload","enrollment":9},{"nctId":"NCT02477631","phase":"PHASE2","title":"Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2016-02","conditions":"Myelodysplastic Syndrome With Low-grade Lesions, Iron Overload Due to Repeated Red Blood Cell Transfusions","enrollment":19},{"nctId":"NCT02878538","phase":"EARLY_PHASE1","title":"A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2018-01","conditions":"Mild Cognitive Impairment","enrollment":""},{"nctId":"NCT02980458","phase":"PHASE1","title":"Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","startDate":"2016-08","conditions":"Bioequivalence","enrollment":25},{"nctId":"NCT02882477","phase":"PHASE2, PHASE3","title":"Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2016-12","conditions":"Diabetes Mellitus, Iron Metabolism Disorders, Gastroduodenal Ulcer","enrollment":20},{"nctId":"NCT02189941","phase":"PHASE1","title":"Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy Volunteers","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2014-05","conditions":"Healthy","enrollment":11},{"nctId":"NCT02442310","phase":"PHASE1","title":"Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2015-05","conditions":"Healthy","enrollment":20},{"nctId":"NCT02465489","phase":"PHASE1","title":"Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2015-06","conditions":"Healthy","enrollment":20},{"nctId":"NCT00105495","phase":"PHASE4","title":"Efficacy Study in Removing Excess Iron From the Heart","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2002-12","conditions":"Thalassemia Major, Hemosiderosis","enrollment":60},{"nctId":"NCT01835496","phase":"PHASE1","title":"Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2013-05","conditions":"Sickle Cell Disease","enrollment":8},{"nctId":"NCT02173951","phase":"PHASE2, PHASE3","title":"An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2014-07","conditions":"Beta Thalassemia Major","enrollment":64},{"nctId":"NCT01996683","phase":"NA","title":"Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2014-11","conditions":"Beta-thalassemia, Serum Ferritin, Iron Chelation Therapy","enrollment":50},{"nctId":"NCT01989455","phase":"PHASE1","title":"A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2013-11","conditions":"Healthy Volunteers","enrollment":64},{"nctId":"NCT01860703","phase":"PHASE4","title":"Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2012-11","conditions":"Prolonged QTc Interval","enrollment":50},{"nctId":"NCT01767103","phase":"PHASE4","title":"An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2013-01","conditions":"Hepatic Impairment","enrollment":21},{"nctId":"NCT01770652","phase":"PHASE4","title":"An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2013-01","conditions":"Renal Impairment","enrollment":32},{"nctId":"NCT02191657","phase":"PHASE1","title":"Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2006-11","conditions":"HIV Infection","enrollment":26},{"nctId":"NCT01838291","phase":"","title":"Active Drug Surveillance Program of Ferriprox Use","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2010-06","conditions":"Transfusional Iron Overload","enrollment":294},{"nctId":"NCT00943748","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2009-10","conditions":"Parkinson's Disease","enrollment":40},{"nctId":"NCT00293098","phase":"","title":"Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease","status":"APPROVED_FOR_MARKETING","sponsor":"Children's Hospital of Philadelphia","startDate":"2006-03","conditions":"Iron Overload","enrollment":""},{"nctId":"NCT01511848","phase":"PHASE2, PHASE3","title":"Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2012-02","conditions":"Beta-thalassemia Major, Sickle Cell Disease, Iron Hemosiderosis","enrollment":60},{"nctId":"NCT00772928","phase":"PHASE3","title":"Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-10","conditions":"Diphtheria, Tetanus, Haemophilus Infection","enrollment":1167},{"nctId":"NCT00897221","phase":"PHASE2","title":"A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2009-06","conditions":"Friedreich's Ataxia","enrollment":36},{"nctId":"NCT00529152","phase":"PHASE3","title":"Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2007-08","conditions":"Iron Overload","enrollment":100}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"APLASIA PURE RED CELL"},{"count":1,"reaction":"BRAIN NATRIURETIC PEPTIDE INCREASED"},{"count":1,"reaction":"BUNDLE BRANCH BLOCK RIGHT"},{"count":1,"reaction":"CATHETER SITE INFECTION"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"CONJUNCTIVITIS"},{"count":1,"reaction":"HEART VALVE INCOMPETENCE"},{"count":1,"reaction":"LEUKAEMIA"},{"count":1,"reaction":"LOBAR PNEUMONIA"},{"count":1,"reaction":"NO THERAPEUTIC RESPONSE"}],"_approvalHistory":[],"publicationCount":1434,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ferriprox (deferiprone)","genericName":"Ferriprox (deferiprone)","companyName":"ApoPharma","companyId":"apopharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ferriprox (deferiprone) is a small molecule used to treat various conditions, including iron overload, sickle cell disease, and other anemias, as well as Parkinson's disease. Its mechanism of action is currently unknown.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}